Comment
doi: 10.1016/S0140-6736(17)31824-X.
Epub 2017 Jul 26.
Bone-forming agents in non-responders to bisphosphonates
Affiliations
- PMID: 28755781
- DOI: 10.1016/S0140-6736(17)31824-X
Item in Clipboard
Comment
Bone-forming agents in non-responders to bisphosphonates
Lancet.
.
No abstract available
Comment on
-
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26. Lancet. 2017. PMID: 28755782
Similar articles
-
Emerging role for bisphosphonates in cancer management.Breast Dis. 2011;33(2):55-7. doi: 10.3233/BD-2010-0328. Breast Dis. 2011. PMID: 22142659 No abstract available.
-
Bisphosphonates for breast cancer: questions answered, questions remaining.Hematol Oncol Clin North Am. 2007 Apr;21(2):341-67. doi: 10.1016/j.hoc.2007.03.004. Hematol Oncol Clin North Am. 2007. PMID: 17512453 Review.
-
[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].Hinyokika Kiyo. 2006 Jun;52(6):491-4. Hinyokika Kiyo. 2006. PMID: 16848364 Japanese.
-
Clinical value of bisphosphonates in cancer therapy.Anticancer Res. 2007 Jul-Aug;27(4A):1759-68. Anticancer Res. 2007. PMID: 17649770 Review.
-
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.Eur J Pharmacol. 2008 Dec 14;600(1-3):140-7. doi: 10.1016/j.ejphar.2008.10.031. Epub 2008 Oct 21. Eur J Pharmacol. 2008. PMID: 18973752
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
